Viking Therapeutics
San Diego
About Viking Therapeutics
Viking Therapeutics is a clinical-stage biotherapeutics company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders. Viking’s research and development activities leverage the Company’s expertise in metabolism to develop innovative therapeutics that improve patients’ lives. The Company’s lead clinical program is VK0612, a first-in-class, orally available drug candidate type 2 diabetes. The Company’s second clinical program is VK5211, an orally available, non-steroidal selective androgen receptor modulator, or SARM, for the treatment of cancer cachexia. Viking is also developing three novel preclinical programs targeted at metabolic diseases and anemia.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Total funding: $1.1B
- Funding stage: IPO
- Last round: Post-IPO Equity (Feb 2024)
- Ticker: nasdaq:VKTX
- Website: vikingtherapeutics.com
- Phone: +1 (858) 550-7810
Industries & Categories
Health Care, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/viking-therapeutics-47164 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.